Cargando…

Clot Waveform Analysis for Hemostatic Abnormalities

Clot waveform analysis (CWA) observes changes in transparency in a plasma sample based on clotting tests such as activated partial thromboplastin time (APTT), prothrombin time (PT), and thrombin time (TT). Evidence indicates that not only an abnormal waveform but also peak times and heights in deriv...

Descripción completa

Detalles Bibliográficos
Autores principales: Wada, Hideo, Shiraki, Katsuya, Matsumoto, Takeshi, Shimpo, Hideto, Shimaoka, Motomu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Laboratory Medicine 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345169/
https://www.ncbi.nlm.nih.gov/pubmed/37387486
http://dx.doi.org/10.3343/alm.2023.43.6.531
_version_ 1785073026485714944
author Wada, Hideo
Shiraki, Katsuya
Matsumoto, Takeshi
Shimpo, Hideto
Shimaoka, Motomu
author_facet Wada, Hideo
Shiraki, Katsuya
Matsumoto, Takeshi
Shimpo, Hideto
Shimaoka, Motomu
author_sort Wada, Hideo
collection PubMed
description Clot waveform analysis (CWA) observes changes in transparency in a plasma sample based on clotting tests such as activated partial thromboplastin time (APTT), prothrombin time (PT), and thrombin time (TT). Evidence indicates that not only an abnormal waveform but also peak times and heights in derivative curves of CWA are useful for the evaluation of hemostatic abnormalities. Modified CWA, including the PT with APTT reagent, dilute PT (small amount of tissue factor [TF]-induced clotting factor IX [FIX] activation; sTF/FIXa), and dilute TT, has been proposed to evaluate physiological or pathological hemostasis. We review routine and modified CWA and their clinical applications. In CWA-sTF/FIXa, elevated peak heights indicate hypercoagulability in patients with cancer or thrombosis, whereas prolonged peak times indicate hypocoagulability in several conditions, including clotting factor deficiency and thrombocytopenia. CWA-dilute TT reflects the thrombin burst, whereas clot-fibrinolysis waveform analysis reflects both hemostasis and fibrinolysis. The relevance and usefulness of CWA-APTT and modified CWA should be further investigated in various diseases.
format Online
Article
Text
id pubmed-10345169
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Korean Society for Laboratory Medicine
record_format MEDLINE/PubMed
spelling pubmed-103451692023-07-15 Clot Waveform Analysis for Hemostatic Abnormalities Wada, Hideo Shiraki, Katsuya Matsumoto, Takeshi Shimpo, Hideto Shimaoka, Motomu Ann Lab Med Review Article Clot waveform analysis (CWA) observes changes in transparency in a plasma sample based on clotting tests such as activated partial thromboplastin time (APTT), prothrombin time (PT), and thrombin time (TT). Evidence indicates that not only an abnormal waveform but also peak times and heights in derivative curves of CWA are useful for the evaluation of hemostatic abnormalities. Modified CWA, including the PT with APTT reagent, dilute PT (small amount of tissue factor [TF]-induced clotting factor IX [FIX] activation; sTF/FIXa), and dilute TT, has been proposed to evaluate physiological or pathological hemostasis. We review routine and modified CWA and their clinical applications. In CWA-sTF/FIXa, elevated peak heights indicate hypercoagulability in patients with cancer or thrombosis, whereas prolonged peak times indicate hypocoagulability in several conditions, including clotting factor deficiency and thrombocytopenia. CWA-dilute TT reflects the thrombin burst, whereas clot-fibrinolysis waveform analysis reflects both hemostasis and fibrinolysis. The relevance and usefulness of CWA-APTT and modified CWA should be further investigated in various diseases. Korean Society for Laboratory Medicine 2023-11-01 2023-06-30 /pmc/articles/PMC10345169/ /pubmed/37387486 http://dx.doi.org/10.3343/alm.2023.43.6.531 Text en © Korean Society for Laboratory Medicine https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Wada, Hideo
Shiraki, Katsuya
Matsumoto, Takeshi
Shimpo, Hideto
Shimaoka, Motomu
Clot Waveform Analysis for Hemostatic Abnormalities
title Clot Waveform Analysis for Hemostatic Abnormalities
title_full Clot Waveform Analysis for Hemostatic Abnormalities
title_fullStr Clot Waveform Analysis for Hemostatic Abnormalities
title_full_unstemmed Clot Waveform Analysis for Hemostatic Abnormalities
title_short Clot Waveform Analysis for Hemostatic Abnormalities
title_sort clot waveform analysis for hemostatic abnormalities
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345169/
https://www.ncbi.nlm.nih.gov/pubmed/37387486
http://dx.doi.org/10.3343/alm.2023.43.6.531
work_keys_str_mv AT wadahideo clotwaveformanalysisforhemostaticabnormalities
AT shirakikatsuya clotwaveformanalysisforhemostaticabnormalities
AT matsumototakeshi clotwaveformanalysisforhemostaticabnormalities
AT shimpohideto clotwaveformanalysisforhemostaticabnormalities
AT shimaokamotomu clotwaveformanalysisforhemostaticabnormalities